Skip to main content

Table 3 Multivariable logistic regression analysis of possible variables (P<0.05 in univariate logistic regression analysis) predicting pCR

From: A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer

 

P

OR

95 % CI

Tumor size

 T1

 

1

 

 T2

0.186

0.576

0.255-1.304

 T3

0.544

0.737

0.275-1.975

 T4

0.015

0.281

0.101-0.779

Hormone receptor status

 Negative

 

1

 

 Positive

<0.001

0.224

0.125-0.400

Regimens

 Cyclophosphamide, epirubicin and 5-fluorouracil

 

1

 

 Cyclophosphamide, epirubicin and 5-fluorouracil followed by paclitaxel or docetaxel and epirubicin

0.208

4.673

0.423-51.590

 Navelbine and epirubicin

0.078

6.999

0.804-60.897

 Paclitaxel and carboplatin or paclitaxel and cisplatin

0.003

27.696

3.131-245.030

Cycles

 3-4

 

1

 

 1-2

0.500

0.579

0.118-2.834

 5-6

0.217

2.338

0.606-9.017

  1. Abbreviations: pCR pathological complete response, OR odds ratio, CI confidence interval